(Q43800002)

English

Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study

scientific article published on 12 April 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

0 references

1 reference

based on heuristic

inferred from title

8

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

author name string

Wieneke A Buikhuisen

1

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Jacobus A Burgers

2

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Andrew D Vincent

3

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Catharina M Korse

4

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Rob J van Klaveren

5

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Franz M N H Schramel

6

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Nick Pavlakis

7

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Frank L J Custers

9

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

J Hugo Schouwink

10

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Steven J M Gans

11

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Harry J M Groen

12

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Wim F M Strankinga

13

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Paul Baas

14

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

publication date

12 April 2013

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

543-551

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Malignant Mesothelioma: Global Incidence and Relationship with Asbestos

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970125-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970125-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Inst

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970125-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumor angiogenesis: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970125-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970125-6

7 January 2021

based on heuristic

inferred from DOI database lookup

SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970125-6

7 January 2021

based on heuristic

inferred from DOI database lookup

VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970125-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970125-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II evaluation of thalidomide in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970125-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970125-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970125-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970125-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970125-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Thalidomide in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970125-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Markers for the non-invasive diagnosis of mesothelioma: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970125-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970125-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Non-invasive diagnosis of pleural malignancies: the role of tumour markers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970125-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970125-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970125-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The evolution of thalidomide and its IMiD derivatives as anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970125-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970125-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970125-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970125-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970125-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970125-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970125-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A Phase II Study of Intermittent Sunitinib Malate as Second-Line Therapy in Progressive Malignant Pleural Mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970125-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum and pleural fluid biomarkers for mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970125-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(13)70125-6

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43800002&oldid=2103445160"